The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Team Psykskallar (Swedish for "psych heads") consisted of Andreas "ruMpel" Rönnberg (level designer, music, and team leader), James "Minuit" Marchant (programmer, modeler, animator, and team leader), Stig "DragonNOR" Sydtangen (QA tester and voice of Simon), Lasse "BerZerk" Holmen (QA tester and voice of the Doctor), Jordy "Sporkeh" Boerema (weapons animator and modeler), and Aina Hatlevik (voice of Sophie). Rönnberg had previously created the Half-Life horror mod Afraid of Monsters (2005) by himself when he was 13 years old. The concept for Cry of Fear started when Rönnberg, who was going through a difficult time in his life, wanted to make "something damn sick and scary" and asked his friend Marchant to join him. The two began working on the project together, then later sought more people for their team. Rönnberg took photographs of Stockholm as a reference to design custom textures of the game's city, which resulted in a photo-realistic appearance. For example, Waspet Gardens is modeled after Humlegården, Saxon Avenue is modeled after Sankt Eriksplan, and the train station is modeled after T-Centralen, the main central subway station in Sweden. The apartments are a replica of the building where Rönnberg's father lived, and one of the earliest created locations in the game. Harbor College is based on the college Rönnberg graduated from, Cyber Gymnasiet, and was originally a 3D project for a class. This allowed Rönnberg to work on Cry of Fear while attending school.
==== Aqueous suspensions ==== Aqueous suspensions are suspensions of crystal particles of a compound in water. Estradiol in microcrystalline aqueous suspension for use by intramuscular injection was previously marketed in the 1950s under brand names such as Aquadiol, Diogyn, Progynon Aqueous Suspension, and Progynon Micropellets. It was used at a dose of 0.5 to 1.5 mg 2 or 3 times per week. Newman (1950) found that 0.5 to 2 mg once per week was satisfactory. As such, the preparation presumably had a duration in the range of 2 to 7 days. Microcrystalline aqueous suspensions of estradiol esters, for instance of estradiol benzoate (brand names Agofollin Depot alone and Follivirin in combination with testosterone isobutyrate), have been found to have longer duration of actions than oil solutions of the same esters when administered via intramuscular injection. Whereas the duration of a single intramuscular injection of amorphous estradiol benzoate in oil solution is 6 days, the duration of a single intramuscular injection of microcrystalline estradiol benzoate in aqueous suspension is 16 to 21 days. The duration of crystalline aqueous suspensions is highly dependent on crystal size. Steroids and steroid fatty acid esters are lipophilic and have very low water solubility. When they are suspended in the form of crystals in water, these crystals dissolve slowly, releasing steroid from their surfaces in the process. The larger the particle sizes of the crystals, the slower the dissolution rate.
== Medical use == Aminocaproic acid (Amicar) is FDA-approved for use in the treatment of acute bleeding due to elevated fibrinolytic activity. It also carries an orphan drug designation from the FDA for the prevention of recurrent hemorrhage in patients with traumatic hyphema. In clinical practice, aminocaproic acid is frequently used off-label for control of bleeding in patients with severe thrombocytopenia, control of oral bleeding in patients with congenital and acquired coagulation disorders, control of perioperative bleeding associated with cardiac surgery, prevention of excessive bleeding in patients on anticoagulation therapy undergoing invasive dental procedures, and reduction of the risk of catastrophic hemorrhage in patients with acute promyelocytic leukemia.
=== Background === In the mid-1960s, the United States and Western Europe planned airliners seating twice the then-maximum of some 200 passengers. They were known as airbuses at the time. The Soviet leadership wanted to match them with an aerobus (Russian: аэробус). Alongside the propaganda motive, the USSR genuinely needed an aerobus. Aeroflot expected over 100 million passengers a year within a decade (the 100th million annual passenger was indeed carried on 29 December 1976.) First to respond was OKB-153, the bureau led by Oleg Antonov. It proposed a 724-seat version of the An-22 airlifter. The project was promoted until 1969, ultimately with a 605-passenger interior (383 on the upper deck and 223 on the lower). It did not go ahead due to fears that it would be old-fashioned and because the Kiev-based bureau was close to the deposed Nikita Khrushchev.
Sources: en.wikipedia.org
Though the push-pull technique was invented as a strategy to control stem-boring moths, such as Chilo partellus, through the manipulation of volatile host-finding cues, it was later discovered that allelopathic substances exuded by the roots of Desmodium spp. also contribute to the suppression of the damaging parasitic weed, Striga.
High-throughput sequencing, which includes next-generation "short-read" and third-generation "long-read" sequencing methods, applies to exome sequencing, genome sequencing, genome resequencing, transcriptome profiling (RNA-Seq), DNA-protein interactions (ChIP-sequencing), and epigenome characterization. The high demand for low-cost sequencing has driven the development of high-throughput sequencing technologies that parallelize the sequencing process, producing thousands or millions of sequences concurrently. High-throughput sequencing technologies are intended to lower the cost of DNA sequencing beyond what is possible with standard dye-terminator methods. In ultra-high-throughput sequencing as many as 500,000 sequencing-by-synthesis operations may be run in parallel. Such technologies led to the ability to sequence an entire human genome in as little as one day. As of 2019, corporate leaders in the development of high-throughput sequencing products included Illumina, Qiagen and ThermoFisher Scientific.
Following the sale of lots, Knoxville's leaders set about constructing a courthouse and jail. A garrison of federal soldiers, under the command of David Henley, erected a blockhouse in Knoxville in 1792. The Cowan brothers, Nathaniel and Samuel, opened the city's first general store in August 1792, and John Chisholm's tavern was in operation by December 1792. The city's first newspaper, the Knoxville Gazette, was established by George Roulstone in November 1791. In 1794, Blount College, the forerunner of the University of Tennessee, was chartered, with Samuel Carrick as its first president. Carrick also established the city's first church, the First Presbyterian Church, though a building wasn't constructed until 1816.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.